MLA Diagnostics has developed a non-invasive melanoma risk assessment tool to identify individuals at high risk of metastasis or recurrence. Using epigenetic tumor information enriched with patient clinical and pathological parameters in an integrated tool, the prognostic assessment of a melanoma patient is improved and clinicians are further supported in clinical decision making. 

As the basis of the epigenetic input, the methylation of the promoter of lymphocyte antigen 75 (LY75) is shown to be a strong predictor of poor clinical outcome. MLA Diagnostics has developed a methylation-specific PCR test which contributes to the clinical risk assessment of recurrence within 5 years.